Trial Profile

A Single Center, Non-Randomized, Phase 1b Study of Orca-T Following Escalated Dose of Total Marrow and Lymphoid Irradiation in Patients With Acute Leukemias and MDS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fludarabine (Primary) ; Melphalan (Primary) ; Orca-T (Primary) ; Tacrolimus (Primary) ; Thiotepa (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

09 Dec 2024 According to a Orca Bio media release, data from the study were presented at the 66th American Society of Hematology (ASH) Annual Meeting.
09 Dec 2024 Results (Three-Year Survival Data, n=77) presented in the Orca Bio Media Release.
23 Feb 2024 Results from a subgroup analysis of this trial presented in a Orca Bio media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com